Compare Crowdstrike Holdings Inc (CRWD) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Cytokinetics Inc — how do they compare? Crowdstrike Holdings Inc trades at $221.58 (market cap $225.95B), while Cytokinetics Inc trades at $76.67 (market cap $10.63B). The key difference: Crowdstrike Holdings Inc is far larger — about 21.3× Cytokinetics Inc's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CRWD | CYTK | |
|---|---|---|
Market Cap | $225.95B | $10.63B |
Sector | Technology | Technology |
52-Week High | $225.16 | $87.26 |
52-Week Low | $87.56 | $34.31 |
Enterprise Value | $222.22B | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $221.85, down 1.47% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth remains strong, reaching $3.95 billion in 2025, though net income margins are negative. Recent news highlights leadership in cybersecurity and AI-driven threat detection, with the stock up 106% over six months. A 1:4 stock split occurred on July 2, 2026.
The stock offers growth exposure to cybersecurity demand, supported by analyst optimism and platform consolidation, but carries high valuation multiples and profitability risks. Upside depends on sustained revenue expansion and margin improvement, while volatility and competitive pressures pose challenges.
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
